Metrics Now Offers Microbiology Testing
Metrics Inc. now offers microbiology-testing services to the contract pharmaceutical industry
METRICS NOW OFFERS MICROBIOLOGY TESTING
New microbiology services part of $18-million facility expansion doubling Metrics' size
GREENVILLE, N.C.- Metrics Inc. now offers microbiology-testing services to the contract pharmaceutical industry.
The new services stem from the company's recent $18-million, 47,000-square-foot expansion that doubled its facility size and dramatically grew the company’s service capabilities to clients.
Metrics Inc., headquartered in Greenville, N.C., is one of the fastest-growing contract pharmaceutical development laboratories in the United States. Metrics provides quality pharmaceutical formulation, clinical trial material (Phase I, II and III) and commercial manufacturing, and analytical development/validation services to the pharmaceutical industry.
"Offering our clients all the services they need under one roof has been a long-time goal for us," said Phil Hodges, president. "We're glad we can add value to the relationships we've developed with our clients, and know these services will make Metrics even more competitive when it comes to attracting new clients."
As part of its new microbiology laboratory, Metrics has brought antibiotic assay and sterility testing online, enhancing its ability to offer full microbiological support of sterile products. The company routinely performs bacterial endotoxin and particulate matter testing on parenterals.
Metrics' facility addition also includes four new fully operational analytical laboratories, validated and ready to handle projects; stability storage with state-of-the-art environmental specialties chambers complete with redundant mechanical systems and strictly limited personnel access; and a dedicated cytotoxic and potent compound laboratory.
For more information about Metrics, visit www.metricsinc.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
